Metamizol Hexal

Metamizole sodium, the active ingredient in Metamizol Hexal, is a pyrazolone presented as an oral dosage form for oral use. It belongs to the analgesic and antipyretic therapeutic class and is indicated for the treatment of acute pain, fever, and post‑operative pain in adult patients.

GNH USA supplies Metamizol Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality through stringent manufacturing standards and provides regulatory documentation to support import and distribution across EU and other markets.

Metamizol Hexal, a pyrazolone analgesic and antipyretic, is used in conditions where pain or fever requires rapid relief.

- Acute pain: provides effective analgesia for short‑term severe pain. - Fever: reduces elevated body temperature in febrile states. - Post‑operative pain: helps control discomfort following surgical procedures.

Metamizol Hexal may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional emesis. - Dizziness: transient light‑headedness. - Headache: mild cranial discomfort. - Rash: skin redness or mild itching. - Hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Anaphylaxis: life‑threatening allergic reaction. - Stevens‑Johnson syndrome: severe skin and mucous membrane disorder. - Blood dyscrasias: abnormal blood cell counts. - Severe hypotension: marked blood pressure decline. - Hepatic failure: rare liver injury.

Before prescribing Metamizol Hexal, clinicians should consider several safety measures.

- Assess blood counts before initiating therapy: monitor for agranulocytosis. - Avoid use in patients with known hypersensitivity: risk of severe allergic reaction. - Use with caution in renal or hepatic impairment: adjust monitoring. - Do not combine with other NSAIDs or anticoagulants without supervision: increased bleeding risk. - Pregnancy and breastfeeding: consult physician, limited safety data. - Store at ambient temperature: keep in original packaging, protect from moisture.

Metamizol Hexal can interact with other medicines, requiring attention to potential risks.

Major Interactions (Avoid): - Concurrent use with other myelosuppressive agents: risk of severe bone‑marrow suppression. - Combination with sulfonamides: increased risk of agranulocytosis. - Co‑administration with anticoagulants: enhanced bleeding tendency.

Moderate Interactions (Monitor Closely): - Interaction with ACE inhibitors: may potentiate hypotensive effect. - Use with diuretics: monitor electrolyte balance. - Concurrent use with other analgesics: assess cumulative toxicity.